articleThe LancetMar 27, 2024Closed access

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

PAPeter A. CampochiaroRLRobert L. AveryDMDavid M. BrownJSJeffrey S. HeierACAllen C. Ho

Johns Hopkins Medicine · Johns Hopkins University · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

110
total citations
FWCI
52.93
Percentile
100%
References
18
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Macular degeneration
  • Medicine
  • Choroidal neovascularization
  • Ophthalmology
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding